“…Recently, there has been a consistent escalation in the global occurrence of MM, imposing a huge economic burden on society [ 17 , 18 ]. Early surgical excision is the primary treatment approach for non-metastatic cutaneous malignant melanoma, yielding favorable survival outcomes [ 19 , 20 ]. In recent years, despite the significant shift in treatment approach for advanced melanoma through the use of targeted therapy and immunotherapy, the risk of mortality in metastatic melanoma remains very high [ 21 ].…”